Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder
Sign Up to like & getrecommendations! Published in 2018 at "Pharmacogenomics and Personalized Medicine"
DOI: 10.2147/pgpm.s160763
Abstract: Background Fluvoxamine therapy is used for treatment of patients with depressive disorder, but it is often ineffective, and some patients suffer from dose-dependent undesirable side effects such as vertigo, headache, indigestion, xerostomia, increased anxiety, etc.… read more here.
Keywords: patients depressive; fluvoxamine; depressive disorder; efficacy safety ... See more keywords